Showing results (501-510 of 548) with videos related to
Sort By:
Pageof 55
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.Cancer Discovery|August 20, 2013
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphomaThomas Clozel, ShaoNing Yang, Rebecca L Elstrom, et al.Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.Blood|March 12, 2014
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphomaIan W Flinn, Brad S Kahl, John P Leonard, et al.Blood|April 2, 2020
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical TrialHeiko Schöder, Mei-Yin C Polley, Michael V Knopp, et al.Blood|February 16, 2023
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCLJia Ruan, Alison Moskowitz, Neha Mehta-Shah, et al.International Journal of Oncology|December 28, 2010
The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp functionLilly Chai, Rajashree P McLaren, Ann Byrne, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.Cancer Discovery|February 25, 2017
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma CellsEster Valls, Camille Lobry, Huimin Geng, et al.Pageof 55